Davis R M Inc. Has $21.11 Million Stake in Zoetis Inc. (NYSE:ZTS)

Davis R M Inc. decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 129,552 shares of the company’s stock after selling 3,563 shares during the period. Davis R M Inc.’s holdings in Zoetis were worth $21,108,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Callahan Advisors LLC grew its holdings in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after buying an additional 6,221 shares during the last quarter. Pensionfund Sabic grew its holdings in Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares during the last quarter. CIBC Asset Management Inc grew its holdings in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after buying an additional 46,050 shares during the last quarter. PFW Advisors LLC acquired a new stake in Zoetis in the 4th quarter valued at approximately $1,764,000. Finally, Alberta Investment Management Corp grew its holdings in Zoetis by 2,050.0% in the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after buying an additional 28,700 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $171.70 on Tuesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $76.89 billion, a PE ratio of 31.39, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.33. The business has a 50 day simple moving average of $166.91 and a 200 day simple moving average of $176.66.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZTS. Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Piper Sandler lifted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.